|Alimta Side Effects and Warnings
|ALIMTA is approved by the FDA in combination with cisplatin (another
chemotherapy drug) for the initial treatment of advanced nonsquamous
non-small cell lung cancer (NSCLC), a specific type of NSCLC. ALIMTA is not
indicated for patients who have a different type of NSCLC called squamous cell.